Belite Bio, Inc. Sponsored ADR (BLTE) vs CG Oncology, Inc. (CGON)
Belite Bio, Inc. Sponsored ADR and CG Oncology, Inc. are both Biotechnology companies. Belite Bio, Inc. Sponsored ADR is the larger, with a market value of $6.8B against $6.1B — 1.1× the size. Belite Bio, Inc. Sponsored ADR has the higher net margin (0.00% vs −3,602.7%) and the higher return on invested capital (−9.55% vs −4,111.6%). Across the 13 metrics below, Belite Bio, Inc. Sponsored ADR leads on 10 and CG Oncology, Inc. on 3.
Valuation
Profitability
| Metric | BLTE | CGON | Biotechnology median |
|---|---|---|---|
| Gross margin | — | (85.20%) | 65.16% |
| Operating margin | 0.00% | (4,056.18%) | 0.00% |
| Net margin | 0.00% | (3,602.68%) | 0.00% |
| Free cash flow margin | 0.00% | (2,879.62%) | 0.00% |
| Return on equity | 0.00% | (26.41%) | (57.72%) |
| Return on assets | (21.60%) | (25.11%) | (49.22%) |
| Return on invested capital | (9.55%) | (4,111.64%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack